Notably, each member of the pathway has been implicated with TNBC tumorigenicity in vivo: MBD2_v2 and SRSF2 by our laboratory [12, 32, 33], NANOG by Thiagarajan et al., TARDBP by Ke et al. [67], and TET1 by Wu and colleagues.[68] Beyond breast cancer, OGT is increased as a biomarker for tumorigenesis, invasion, and poor prognosis in colon cancer [69]. Here, NANOG is linked to malignant colon neoplasm.